{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T20:28:29Z","timestamp":1722889709466},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2006,3,1]],"date-time":"2006-03-01T00:00:00Z","timestamp":1141171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2006,3]]},"DOI":"10.1007\/s11899-006-0019-2","type":"journal-article","created":{"date-parts":[[2007,5,25]],"date-time":"2007-05-25T05:30:39Z","timestamp":1180071039000},"page":"60-65","source":"Crossref","is-referenced-by-count":2,"title":["Nodular lymphocyte-predominant Hodgkin\u2019s lymphoma"],"prefix":"10.1007","volume":"1","author":[{"given":"Lucia","family":"Nogov\u00e0","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Engert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the German Hodgkin Study Group","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1200\/JCO.1999.17.3.776","volume":"17","author":"V Diehl","year":"1999","unstructured":"Diehl V, Sextro M, Franklin J, et al.: Clinical presentation, course and prognostic factors in lymphocyte-predominant Hodgkin\u2019s disease and lymphocyte-rich classical Hodgkin\u2019s disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin\u2019s Disease.J Clin Oncol 1999, 17:776\u2013783. The large retrospective study comparing clinical patterns between lymphocyte-predominant Hodgkin\u2019s lymphoma (LPHL) and classical Hodgkin\u2019s lymphoma.","journal-title":"J Clin Oncol"},{"key":"19_CR2","first-page":"1889","volume":"96","author":"I Anagnostopoulos","year":"2000","unstructured":"Anagnostopoulos I, Hansmann ML, Franssila K, et al.: European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunhistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000, 96:1889\u20131899.","journal-title":"Blood"},{"key":"19_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/1097-0142(19870101)59:1<99::AID-CNCR2820590122>3.0.CO;2-J","volume":"59","author":"MA Trudel","year":"1987","unstructured":"Trudel MA, Krikorian JG, Neiman RS: Lymphocyte predominant Hodgkin\u2019s disease: a clinicopathologic reassessment. Cancer 1987, 59:99\u2013106.","journal-title":"Cancer"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/oxfordjournals.annonc.a059244","volume":"6","author":"I Pappa","year":"1995","unstructured":"Pappa I, Norton AJ, Gupta RK, et al.: Nodular type of lymphocyte predominant Hodgkin\u2019s disease. Ann Oncol 1995, 6:559\u2013565.","journal-title":"Ann Oncol"},{"key":"19_CR5","first-page":"187","volume-title":"Hematology 2001: American Society of Hematology Education Program Book","author":"JM Connors","year":"2001","unstructured":"Connors JM: Lymphocyte-predominant Hodgkin\u2019s lymphoma. In Hematology 2001: American Society of Hematology Education Program Book. Edited by Schecter GP, Broudy VC, Williams ME. Washington, DC: American Society of Hematology; 2001:187\u2013190."},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1182\/blood.V101.2.420","volume":"101","author":"U Rehwald","year":"2003","unstructured":"Rehwald U, Schulz H, Reiser M, et al.: Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 2003, 101:420\u2013424. The first study demonstrating the feasibility of rituximab treatment in LPHL.","journal-title":"Blood"},{"key":"19_CR7","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1182\/blood-2002-08-2644","volume":"101","author":"BC Ekstrand","year":"2003","unstructured":"Ekstrand BC, Lucas JB, Horwitz SM, et al.: Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003, 101:4285\u20134289.","journal-title":"Blood"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1093\/annonc\/mdi323","volume":"16","author":"L Nogov\u2019a","year":"2005","unstructured":"Nogov\u2019a L, Reineke T, Eich HT, et al.: Extended fleld radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin\u2019s lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005, 16:1683\u20131687.","journal-title":"Ann Oncol"},{"key":"19_CR9","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1200\/JCO.2003.01.079","volume":"15","author":"B Pellegrino","year":"2003","unstructured":"Pellegrino B, Terrier-Lacombe MJ, Oberlin O, et al.: Lymphocyte-predominant Hodgkin\u2019s lymphoma in children: therapeutic abstention after initial lymph node resection\u2014a study of the French Society of Paediatric Oncology. J Clin Oncol 2003, 15:2948\u20132952. Retrospective analysis of watch-and-wait strategy in children with localized LPHL.","journal-title":"J Clin Oncol"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1097\/00043426-200309000-00003","volume":"25","author":"SB Murphy","year":"2003","unstructured":"Murphy SB, Morgan ER, Katzenstein HM, Kletzel M: Results of little or no treatment for lymphocyte-predominant Hodgkin disease in children and adolescents. J Pediatr Hematol Oncol 2003, 25:684\u2013687.","journal-title":"J Pediatr Hematol Oncol"},{"key":"19_CR11","volume-title":"Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, et al.: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001."},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1365-2559.1990.tb01084.x","volume":"16","author":"DS Nicholas","year":"1990","unstructured":"Nicholas DS, Harris S, Wright DH: Lymphocyte predominance Hodgkin disease: an immunohistochemical study. Histopathology 1990, 16:157\u2013165.","journal-title":"Histopathology"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1470-2045(03)01319-6","volume":"5","author":"RK Thomas","year":"2004","unstructured":"Thomas RK, Re D, Wolf J, et al.: Part I: Hodgkin\u2019s lymphoma\u2014molecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncol 2004, 5:11\u201318.","journal-title":"Lancet Oncol"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"9337","DOI":"10.1073\/pnas.94.17.9337","volume":"94","author":"A Braeuninger","year":"1997","unstructured":"Braeuninger A, Kueppers R, Strickler JG, et al.: Hodgkin and Reed-Sternberg cells in lymphocyte predominance Hodgkin disease represent clonal populations of germinal center-derived tumor cells. Proc Natl Acad Sci U S A 1997, 94:9337\u20139342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2003-05-1487","volume":"103","author":"T Marafioti","year":"2004","unstructured":"Marafioti T, Pozzobon M, Hansmann ML, et al.: Expression of intracellular signalling molecules in classical and lymphocyte predominance Hodgkin disease. Blood 2004, 103:188\u2013193.","journal-title":"Blood"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1080\/1042819031000123528","volume":"44","author":"JZ Huang","year":"2003","unstructured":"Huang JZ, Weisenburger DD, Vose JM, et al.: Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma. A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2003, 44:1903\u20131910.","journal-title":"Leuk Lymphoma"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1600-0609.2005.00462.x","volume":"66","author":"L Nogov\u2019a","year":"2005","unstructured":"Nogov\u2019a L, Reineke T, Josting A, et al.: Lymphocyte-predominant and classical Hodgkin\u2019s lymphoma-3comparison of outcomes. Eur J Haematol Suppl 2005, 66:106\u2013110.","journal-title":"Eur J Haematol Suppl"},{"issue":"suppl 2","key":"19_CR18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1093\/annonc\/2.suppl_2.77","volume":"2","author":"JM Cosset","year":"1991","unstructured":"Cosset JM, Henry-Amar M, Meerwaldt JH: Long-term toxicity of early stages of Hodgkin\u2019s disease therapy: the EORTC experience. Ann Oncol 1991, 2(suppl 2):77\u201382.","journal-title":"Ann Oncol"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cncr.21303","volume":"104","author":"A Wirth","year":"2005","unstructured":"Wirth A, Yuen K, Barton M, et al.: Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma. Cancer 2005, 104:1221\u20131229.","journal-title":"Cancer"},{"key":"19_CR20","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00130404-200209000-00008","volume":"8","author":"PJ Schlembach","year":"2002","unstructured":"Schlembach PJ, Wilder RB, Jones D, et al.: Radiotherapy alone for lymphocyte predominant Hodgkin\u2019s disease. Cancer J 2002, 8:377\u2013383.","journal-title":"Cancer J"},{"key":"19_CR21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clon.2004.07.004","volume":"17","author":"PJ Hoskin","year":"2005","unstructured":"Hoskin PJ, Smith P, Maughan TS, et al.: British National Lymphoma Investigation: Long-term results of a randomised trial of involved fleld radiotherapy vs extended fleld radiotherapy in stage I and II Hodgkin lymphoma. Clin Oncol (R Coll Radiol) 2005, 17:47\u201353.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"Suppl 4","key":"19_CR22","doi-asserted-by":"crossref","first-page":"S107","DOI":"10.1016\/S0959-8049(01)00446-4","volume":"38","author":"J Raemaekers","year":"2002","unstructured":"Raemaekers J, Kluin-Nelemans H, Teodorovic I, et al.: The achievements of the EORTC Lymphoma Group. European Organisation for Research and Treatment of Cancer. Eur J Cancer 2002, 38(Suppl 4):S107-S113.","journal-title":"Eur J Cancer"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1002\/cncr.10404","volume":"94","author":"RB Wilder","year":"2002","unstructured":"Wilder RB, Schlembach PJ, Jones D, et al.: European Organization for Research and Treatment of Cancer and Groupe d\u2019Etude des Lymphomes de l\u2019Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease. Cancer 2002, 94:1731\u20131738.","journal-title":"Cancer"},{"key":"19_CR24","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1182\/blood-2004-02-0567","volume":"104","author":"P Feugier","year":"2004","unstructured":"Feugier P, Labouyrie E, Djeridane M, et al.: Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation. Blood 2004, 104:2675\u20132681. Analysis comparing outcome between patients with LPHL and classical Hodgkin\u2019s lymphoma without mediastinal involvement.","journal-title":"Blood"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"5739","DOI":"10.1200\/JCO.2005.17.970","volume":"23","author":"A Shimabukuro-Vornhagen","year":"2005","unstructured":"Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al.: Lymphocyte-rich classical Hodgkin\u2019s lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin\u2019s Study Group trials. J Clin Oncol 2005, 23:5739\u20135745.","journal-title":"J Clin Oncol"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-006-0019-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-006-0019-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-006-0019-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T00:08:09Z","timestamp":1559434089000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-006-0019-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s11899-006-0019-2","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"type":"print","value":"1558-8211"},{"type":"electronic","value":"1558-822X"}],"subject":[],"published":{"date-parts":[[2006,3]]}}}